| Hy-vee Healthmarket Rx (7078) | |
| 220 Center Town Plz N, Stewartville, Minnesota 55976 | |
| (507) 533-4245 |
| Name | Hy-vee Healthmarket Rx (7078) |
|---|---|
| Organization Name | Hy Vee Inc |
| Location | 220 Center Town Plz N, Stewartville, Minnesota 55976 |
| Type | Pharmacy |
| Phone | (507) 533-4245 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Enzo Biochem, Inc., announced today that it has streamlined its operations, which is anticipated to result in a reduction in annualized operating expenses of more than $4 million beginning in the fiscal 2011 first quarter. These initiatives are also expected to result in increased gross margins. The Company believes that the operating cost reductions, which affect all of its operating businesses as well as corporate overhead, will result in Enzo generating positive cash flow from operations in 2011.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.
A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.
› Verified 5 days ago
| NPI Number | 1336233733 |
| Organization Name | SNYDERS DRUG STORES INC |
| Doing Business As | SNYDER DRUG STORE |
| Type | Pharmacy |
| Address | 220 Center Town Plz N, Stewartville, MN 55976 |
| Phone Number | 507-533-4245 |
News Archive
Enzo Biochem, Inc., announced today that it has streamlined its operations, which is anticipated to result in a reduction in annualized operating expenses of more than $4 million beginning in the fiscal 2011 first quarter. These initiatives are also expected to result in increased gross margins. The Company believes that the operating cost reductions, which affect all of its operating businesses as well as corporate overhead, will result in Enzo generating positive cash flow from operations in 2011.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.
A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.
› Verified 5 days ago
| NPI Number | 1750849220 |
| Organization Name | HY-VEE INC |
| Doing Business As | HY-VEE HEALTHMARKET RX (7078) |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 220 Center Town Plz N, Stewartville, MN 55976 |
| Phone Number | 507-533-4245 |
News Archive
Enzo Biochem, Inc., announced today that it has streamlined its operations, which is anticipated to result in a reduction in annualized operating expenses of more than $4 million beginning in the fiscal 2011 first quarter. These initiatives are also expected to result in increased gross margins. The Company believes that the operating cost reductions, which affect all of its operating businesses as well as corporate overhead, will result in Enzo generating positive cash flow from operations in 2011.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.
A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.
› Verified 5 days ago
News Archive
Enzo Biochem, Inc., announced today that it has streamlined its operations, which is anticipated to result in a reduction in annualized operating expenses of more than $4 million beginning in the fiscal 2011 first quarter. These initiatives are also expected to result in increased gross margins. The Company believes that the operating cost reductions, which affect all of its operating businesses as well as corporate overhead, will result in Enzo generating positive cash flow from operations in 2011.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.
A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.
› Verified 5 days ago
Hy-vee Healthmarket Rx (7078) Type: Pharmacy Location: 220 Center Town Plz N, Stewartville, Minnesota 55976 Phone: (507) 533-4245 |